GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Cyclically Adjusted Price-to-FCF

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Cyclically Adjusted Price-to-FCF : 20.92 (As of Jun. 23, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Cyclically Adjusted Price-to-FCF?

As of today (2024-06-23), Shanghai Kaibao Pharmaceutical Co's current share price is ¥5.44. Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ¥0.26. Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF for today is 20.92.

The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

SZSE:300039' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 17.09   Med: 28   Max: 58.75
Current: 21.2

During the past years, Shanghai Kaibao Pharmaceutical Co's highest Cyclically Adjusted Price-to-FCF was 58.75. The lowest was 17.09. And the median was 28.00.

SZSE:300039's Cyclically Adjusted Price-to-FCF is ranked better than
63.04% of 322 companies
in the Drug Manufacturers industry
Industry Median: 30.14 vs SZSE:300039: 21.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Shanghai Kaibao Pharmaceutical Co's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ¥0.069. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ¥0.26 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Shanghai Kaibao Pharmaceutical Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Cyclically Adjusted Price-to-FCF Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.46 22.53 27.50 33.70 26.02

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.55 28.77 27.22 26.02 23.86

Competitive Comparison of Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.



Shanghai Kaibao Pharmaceutical Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=5.44/0.26
=20.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Shanghai Kaibao Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.069/115.2271*115.2271
=0.069

Current CPI (Mar. 2024) = 115.2271.

Shanghai Kaibao Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.050 98.200 0.059
201409 0.024 98.900 0.028
201412 0.053 99.000 0.062
201503 0.005 99.900 0.006
201506 0.054 99.500 0.063
201509 0.084 100.500 0.096
201512 0.114 100.600 0.131
201603 0.068 102.200 0.077
201606 0.056 101.400 0.064
201609 0.062 102.400 0.070
201612 0.082 102.600 0.092
201703 0.064 103.200 0.071
201706 0.010 103.100 0.011
201709 0.069 104.100 0.076
201712 0.040 104.500 0.044
201803 0.009 105.300 0.010
201806 0.075 104.900 0.082
201809 0.064 106.600 0.069
201812 0.075 106.500 0.081
201903 0.056 107.700 0.060
201906 0.063 107.700 0.067
201909 0.043 109.800 0.045
201912 0.143 111.200 0.148
202003 0.076 112.300 0.078
202006 0.030 110.400 0.031
202009 0.090 111.700 0.093
202012 0.030 111.500 0.031
202103 -0.023 112.662 -0.024
202106 0.099 111.769 0.102
202109 0.007 112.215 0.007
202112 -0.003 113.108 -0.003
202203 0.083 114.335 0.084
202206 0.044 114.558 0.044
202209 0.096 115.339 0.096
202212 0.106 115.116 0.106
202303 0.071 115.116 0.071
202306 0.086 114.558 0.087
202309 0.104 115.339 0.104
202312 0.077 114.781 0.077
202403 0.069 115.227 0.069

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Shanghai Kaibao Pharmaceutical Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines